GSK Bets on Long-Acting Biologics and AI to Reshape Respiratory Care

GSK highlighted progress in its respiratory and immunology pipeline, with a strategy centered on longer-acting biologics, more targeted patient selection and combination treatments. The available article excerpt provides no trial data, financial figures, regulatory milestones or guidance changes, limiting the immediate valuation impact.